Press Release

24 October 2018

Immunicum AB: Invitation to Investor Events in Gothenburg and Stockholm

Immunicum AB (publ; IMMU.ST) announced today that the Company will host two investor events in October. At both events, Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session.   

Gothenburg
Date: Monday, October 29, 2018
Time: 17.30 - 20.00 Central European Time
Location:  First Hotel G
                  Nils Ericsonsplatsen 4
                  411 03 Gothenburg, Sweden

Stockholm
Date: Tuesday, October 30, 2018
Time: 17.30 - 20.00 Central European Time
Location:  Ingenjörshuset Citykonferensen
                  Plan 1 
                  Malmskillnadsgatan 46
                  111 84 Stockholm, Sweden

To register to attend the events,  please send an email to info@immunicum.com with your full name and the selected location (Stockholm or Gothenburg).

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com 

Media Relations

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.  www.immunicum.com